This company is no longer active
Catalyst Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Catalyst Biosciences has a total shareholder equity of $3.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.0M and $6.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.23m |
| Equity | US$3.52m |
| Total liabilities | US$6.45m |
| Total assets | US$9.96m |
Recent financial health updates
Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11
Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Financial Position Analysis
Short Term Liabilities: CBIO's short term assets ($5.1M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: CBIO's short term assets ($5.1M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: CBIO is debt free.
Reducing Debt: CBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBIO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if CBIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/31 06:37 |
| End of Day Share Price | 2023/10/30 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Catalyst Biosciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | B. Riley Securities, Inc. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Kevin DeGeeter | Ladenburg Thalmann & Company |